Mitochondrial Dysfunction in Parkinson's Disease
- PMID: 26113789
- PMCID: PMC4479806
- DOI: 10.5607/en.2015.24.2.103
Mitochondrial Dysfunction in Parkinson's Disease
Abstract
Parkinson's disease (PD) is characterized by the selective loss of dopaminergic neurons of the substantia nigra pars compacta (SNc) with motor and nonmotor symptoms. Defective mitochondrial function and increased oxidative stress (OS) have been demonstrated as having an important role in PD pathogenesis, although the underlying mechanism is not clear. The etiopathogenesis of sporadic PD is complex with variable contributions of environmental factors and genetic susceptibility. Both these factors influence various mitochondrial aspects, including their life cycle, bioenergetic capacity, quality control, dynamic changes of morphology and connectivity (fusion, fission), subcellular distribution (transport), and the regulation of cell death pathways. Mitochondrial dysfunction has mainly been reported in various non-dopaminergic cells and tissue samples from human patients as well as transgenic mouse and fruit fly models of PD. Thus, the mitochondria represent a highly promising target for the development of PD biomarkers. However, the limited amount of dopaminergic neurons prevented investigation of their detailed study. For the first time, we established human telomerase reverse transcriptase (hTERT)-immortalized wild type, idiopathic and Parkin deficient mesenchymal stromal cells (MSCs) isolated from the adipose tissues of PD patients, which could be used as a good cellular model to evaluate mitochondrial dysfunction for the better understanding of PD pathology and for the development of early diagnostic markers and effective therapy targets of PD. In this review, we examine evidence for the roles of mitochondrial dysfunction and increased OS in the neuronal loss that leads to PD and discuss how this knowledge further improve the treatment for patients with PD.
Keywords: PD genes; mitochondrial dysfunction; oxidative stress; pathophysiology.
Figures
Similar articles
-
Mitochondrial dysfunction of immortalized human adipose tissue-derived mesenchymal stromal cells from patients with Parkinson's disease.Exp Neurobiol. 2013 Dec;22(4):283-300. doi: 10.5607/en.2013.22.4.283. Epub 2013 Dec 31. Exp Neurobiol. 2013. PMID: 24465144 Free PMC article.
-
Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.Exp Neurol. 2009 Aug;218(2):235-46. doi: 10.1016/j.expneurol.2009.03.006. Epub 2009 Mar 18. Exp Neurol. 2009. PMID: 19303005 Review.
-
Mitochondrial dysfunction in Parkinson's disease.Transl Neurodegener. 2016 Jul 22;5:14. doi: 10.1186/s40035-016-0060-6. eCollection 2016. Transl Neurodegener. 2016. PMID: 27453777 Free PMC article. Review.
-
Mfn2 protects dopaminergic neurons exposed to paraquat both in vitro and in vivo: Implications for idiopathic Parkinson's disease.Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1359-1370. doi: 10.1016/j.bbadis.2017.02.016. Epub 2017 Feb 16. Biochim Biophys Acta Mol Basis Dis. 2017. PMID: 28215578 Free PMC article.
-
IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: implications for Parkinson's disease.Free Radic Res. 2016 Aug;50(8):853-60. doi: 10.1080/10715762.2016.1185519. Epub 2016 May 24. Free Radic Res. 2016. PMID: 27142242
Cited by
-
Combinatorial glucose, nicotinic acid and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease.Hum Mol Genet. 2021 May 12;30(7):536-551. doi: 10.1093/hmg/ddab059. Hum Mol Genet. 2021. PMID: 33640978 Free PMC article.
-
Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity.Acta Pharmacol Sin. 2016 Sep;37(10):1315-1324. doi: 10.1038/aps.2016.42. Epub 2016 Jul 4. Acta Pharmacol Sin. 2016. PMID: 27374489 Free PMC article.
-
Doxycycline inhibits dopaminergic neurodegeneration through upregulation of axonal and synaptic proteins.Naunyn Schmiedebergs Arch Pharmacol. 2023 Aug;396(8):1787-1796. doi: 10.1007/s00210-023-02435-3. Epub 2023 Feb 27. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36843128
-
3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing.Adv Sci (Weinh). 2018 Nov 20;6(1):1800927. doi: 10.1002/advs.201800927. eCollection 2019 Jan 9. Adv Sci (Weinh). 2018. PMID: 30643711 Free PMC article.
-
Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis.Int J Mol Sci. 2019 Jun 25;20(12):3108. doi: 10.3390/ijms20123108. Int J Mol Sci. 2019. PMID: 31242683 Free PMC article. Review.
References
-
- Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4:600–609. - PubMed
-
- Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006;7:207–219. - PubMed
-
- Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, Stern Y. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol. 1992;49:492–497. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous